Access the full text.
Sign up today, get DeepDyve free for 14 days.
Nelson (1979)
118Anesthesiology, 50
M. Link, L. Berkow, P. Kudenchuk, H. Halperin, E. Hess, V. Moitra, R. Neumar, B. O’Neil, J. Paxton, S. Silvers, Roger White, D. Yannopoulos, M. Donnino (2015)
Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.Circulation, 132 18 Suppl 2
L. Heytens, P. Forget, Jean-Louis Scholtes, F. Veyckemans (2015)
The Changing Face of Malignant Hyperthermia: Less Fulminant, More InsidiousAnaesthesia and Intensive Care, 43
B. Brandom, M. Larach, Min-Shue Chen, M. Young (2011)
Complications Associated with the Administration of Dantrolene 1987 to 2006: A Report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United StatesAnesthesia & Analgesia, 112
R. Gray (2017)
Anesthesia‐induced rhabdomyolysis or malignant hyperthermia: is defining the crisis important?Pediatric Anesthesia, 27
M. Larach, A. Localio, G. Allen, M. Denborough, F. Ellis, G. Gronert, R. Kaplan, S. Muldoon, T. Nelson, H. Ørding, H. Rosenberg, B. Waud, D. Wedel (1994)
A Clinical Grading Scale to Predict Malignant Hyperthermia SusceptibilityAnesthesiology, 80
(1982)
Dantrolene in human malignant hyperthermia, 56
Britt (1974)
108Anesthesia Progress, 21
M. Larach, B. Brandom, G. Allen, G. Gronert, E. Lehman (2014)
Malignant Hyperthermia Deaths Related to Inadequate Temperature Monitoring, 2007–2012: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United StatesAnesthesia & Analgesia, 119
(2019)
Multicenter Perioperative Outcomes Group
S. Riazi, N. Kraeva, P. Hopkins (2018)
Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.Anesthesiology, 128 1
I. Stiell, L. Macle (2011)
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department.The Canadian journal of cardiology, 27 1
M. Kraft, Imad Btaiche, G. Sacks, K. Kudsk (2005)
Treatment of electrolyte disorders in adult patients in the intensive care unit.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 62 16
B. Britt (1974)
Malignant hyperthermia: a pharmacogenetic disease of skeletal and cardiac muscle.Anesthesia progress, 21 4
Amy Dagestad, M. Hermann (2017)
Keeping Cool When Things Heat Up During a Malignant Hyperthermia Crisis.Nursing for women's health, 21 5
M. Musselman, S. Saely (2013)
Diagnosis and treatment of drug-induced hyperthermia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 70 1
A. Panchal, K. Berg, P. Kudenchuk, Marina Rios, K. Hirsch, M. Link, M. Kurz, P. Chan, J. Cabañas, P. Morley, M. Hazinski, M. Donnino (2018)
2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.Circulation, 138 23
M. Larach, Thomas Klumpner, B. Brandom, Michelle Vaughn, K. Belani, A. Herlich, Tae Kim, Janine Limoncelli, S. Riazi, Erica Sivak, J. Capacchione, D. Mashman, S. Kheterpal, F. Kooij, J. Wilczak, R. Soto, Joshua Berris, Zachary Price, Steven Lins, P. Coles, John Harris, K. Cummings, M. Berman, M. Nanamori, B. Adelman, Christopher Wedeven, J. LaGorio, P. McCormick, Simon Tom, M. Aziz, Traci Coffman, Terri Ellis, S. Molina, W. Peterson, S. Mackey, W. Klei, A. Ginde, D. Biggs, M. Neuman, R. Craft, N. Pace, William Paganelli, M. Durieux, B. Nair, J. Wanderer, Scott Miller, Daniel Helsten, Z. Turnbull, R. Schonberger (2019)
Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic ReviewAnesthesiology, 130
Sharon Dirksen, S. Wicklin, D. Mashman, P. Neiderer, Debra Merritt (2013)
Developing effective drills in preparation for a malignant hyperthermia crisis.AORN journal, 97 3
T. Nelson, E. Flewellen (1979)
Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.Anesthesiology, 50 2
R. Brislin, M. Theroux (2013)
Core myopathies and malignant hyperthermia susceptibility: a reviewPediatric Anesthesia, 23
W. Frontera, J. Ochala (2015)
Skeletal Muscle: A Brief Review of Structure and FunctionCalcified Tissue International, 96
P. Hopkins, H. Rüffert, M. Snoeck, T. Girard, K. Glahn, F. Ellis, C. Müller, A. Urwyler (2015)
European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility.British journal of anaesthesia, 115 4
M. Kolb, M. Horne, R. Martz (1982)
Dantrolene in Human Malignant Hyperthermia A Multicenter StudyAnesthesiology, 56
H. Rosenberg, N. Pollock, A. Schiemann, T. Bulger, K. Stowell (2015)
Malignant hyperthermia: a reviewOrphanet Journal of Rare Diseases, 10
K. Glahn, F. Ellis, P. Halsall, C. Müller, M. Snoeck, A. Urwyler, F. Wappler (2010)
Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group.British journal of anaesthesia, 105 4
Fay Mitchell-Brown (2012)
Malignant hyperthermia: turn down the heat.Nursing, 42 5
A. Caen, M. Berg, L. Chameides, C. Gooden, R. Hickey, Halden Scott, R. Sutton, J. Tijssen, A. Topjian, É. Jagt, S. Schexnayder, R. Samson (2015)
Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.Circulation, 132 18 Suppl 2
Malignant hyperthermia (MH) is caused by a genetic disorder of the skeletal muscle that induces a hypermetabolic response when patients are exposed to a triggering agent such as volatile inhaled anesthetics or depolarizing neuromuscular blockers. Symptoms of MH include increased carbon dioxide production, hyperthermia, muscle rigidity, tachypnea, tachycardia, acidosis, hyperkalemia, and rhabdomyolysis. Common scenarios for triggering agents are those used are during surgery and rapid sequence intubation. Hypermetabolic symptoms have a rapid onset; hence, prompt recognition and treatment are vital to prevent morbidity and mortality. The first-line treatment agent for an MH response is dantrolene. Further treatment includes managing complications related to a hypermetabolic response such as hyperkalemia and arrhythmias. This review is focused on the recognition and treatment considerations of MH in the emergency department to optimize therapy and improve patient morbidity and mortality.
Advanced Emergency Nursing Journal – Wolters Kluwer Health
Published: Apr 1, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.